In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH: None known
PREGNANCY: Insufficient data on use in pregnant women. Advise against breastfeeding during treatment and for 40 days after the last dose.
WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA
MENINGOCOCCAL INFECTIONS MAY OCCUR IN PATIENTS TREATED WITH PEGCETACOPLAN AND MAY BECOME RAPIDLY LIFE-THREATENING OR FATAL IF NOT RECOGNIZED AND TREATED EARLY. USE OF PEGCETACOPLAN MAY PREDISPOSE INDIVIDUALS TO SERIOUS INFECTIONS, ESPECIALLY THOSE CAUSED BY ENCAPSULATED BACTERIA, SUCH AS STREPTOCOCCUS PNEUMONIAE, NEISSERIA MENINGITIDIS TYPES A, C, W, Y, AND B, AND HAEMOPHILUS INFLUENZAE TYPE B.
• COMPLY WITH THE MOST CURRENT ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) RECOMMENDATIONS FOR VACCINATIONS AGAINST ENCAPSULATED BACTERIA.
• VACCINATE PATIENTS AGAINST ENCAPSULATED BACTERIA AS RECOMMENDED AT LEAST 2 WEEKS PRIOR TO ADMINISTERING THE FIRST DOSE OF PEGCETACOPLAN UNLESS THE RISKS OF DELAYING PEGCETACOPLAN THERAPY OUTWEIGH THE RISKS OF DEVELOPING A SERIOUS INFECTION.
• VACCINATION REDUCES, BUT DOES NOT ELIMINATE, THE RISK OF SERIOUS INFECTIONS. MONITOR PATIENTS FOR EARLY SIGNS OF SERIOUS INFECTIONS AND EVALUATE IMMEDIATELY IF INFECTION IS SUSPECTED.
PEGCETACOPLAN IS AVAILABLE ONLY THROUGH A RESTRICTED PROGRAM UNDER A RISK EVALUATION AND MITIGATION STRATEGY (REMS). UNDER THE PEGCETACOPLAN REMS, PRESCRIBERS MUST ENROLL IN THE PROGRAM.
See full prescribing information for complete boxed warning
Please login to view the rest of this drug profile.